FdaApplication
ANDA 209253
Identifiers
- fda_app_no: ANDA209253
Properties
| Property | Value |
|---|---|
| applicant_name | ACTAVIS LABORATORIES FL INC |
| application_type | ANDA |
| approval_date | 2023-06-22 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AMPHETAMINE | AMPHETAMINE | EQ 3.1MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL |
| AMPHETAMINE | AMPHETAMINE | EQ 15.7MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL |
| AMPHETAMINE | AMPHETAMINE | EQ 18.8MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL |
| AMPHETAMINE | AMPHETAMINE | EQ 9.4MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL |
| AMPHETAMINE | AMPHETAMINE | EQ 6.3MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL |
| AMPHETAMINE | AMPHETAMINE | EQ 12.5MG BASE | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL |
6 products